FDA Adds Eye Condition Warning to Ozempic and GLP-1s

Buzzline

The FDA is requiring new safety labels for all GLP-1 drugs, including Ozempic, Wegovy, Mounjaro and Zepbound, over a potential increased risk of a rare eye condition that can cause sudden, permanent vision loss in one eye, Euronews reports. The agency reviewed 126 clinical trials involving more than 134,000 patients. Last year, European regulators called the condition a very rare side effect of semaglutide, affecting up to 1 in 10,000 patients. The video covers what the warning says, the evidence and its limits.  Disclosure: This video contains stock footage and content created or enhanced using AI-assisted tools.

Transcript

00:00The FDA is adding new vision loss warnings to popular weight loss and diabetes drugs.

00:05The agency said on Monday it is requiring updated safety labels for all GLP-1 medicines.

00:11That includes Ozempic and Wegevy from Novo Nordisk, and Munjaro and ZepBound from Eli Lilly.

00:17The warning covers a potential increased risk of a rare eye condition called Nayan.

00:22It can cause sudden, painless loss of vision in one eye, including permanent vision loss.

00:26The FDA analyzed 126 clinical trials involving more than 134,000 patients.

00:33It also reviewed real-world data and published observational studies.

00:37The agency acknowledged limitations in the evidence, but it concluded that a potential increased risk justified extra warnings across the

00:45whole drug class.

00:46Last year, the European Medicines Agency classified the condition as a very rare side effect of semaglutide.

00:53It affects up to 1 in 10,000 patients.

00:56The report does not include company statements or the exact wording of the new labels.

01:01Disclosure.

01:02This video contains stock footage and content created or enhanced using AI-assisted tools.

Category

Transcript

Comments

Recommended